BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 15073105)

  • 1. Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
    Yokoi K; Fidler IJ
    Clin Cancer Res; 2004 Apr; 10(7):2299-306. PubMed ID: 15073105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
    Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
    Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase/protein kinase B (PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells.
    Squires MS; Hudson EA; Howells L; Sale S; Houghton CE; Jones JL; Fox LH; Dickens M; Prigent SA; Manson MM
    Biochem Pharmacol; 2003 Feb; 65(3):361-76. PubMed ID: 12527329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
    Arlt A; Gehrz A; Müerköster S; Vorndamm J; Kruse ML; Fölsch UR; Schäfer H
    Oncogene; 2003 May; 22(21):3243-51. PubMed ID: 12761494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
    Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
    Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intravitreal insulin and insulin signaling cascade inhibitors on emmetropization in the chick.
    Penha AM; Burkhardt E; Schaeffel F; Feldkaemper MP
    Mol Vis; 2012; 18():2608-22. PubMed ID: 23112573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor-15 prevents low potassium-induced cell death of cerebellar granule neurons by differential regulation of Akt and ERK pathways.
    Subramaniam S; Strelau J; Unsicker K
    J Biol Chem; 2003 Mar; 278(11):8904-12. PubMed ID: 12514175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
    Baker CH; Solorzano CC; Fidler IJ
    Cancer Res; 2002 Apr; 62(7):1996-2003. PubMed ID: 11929816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
    Holcomb B; Yip-Schneider MT; Matos JM; Dixon J; Kennard J; Mahomed J; Shanmugam R; Sebolt-Leopold J; Schmidt CM
    J Gastrointest Surg; 2008 Feb; 12(2):288-96. PubMed ID: 18049840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway.
    Qiao M; Shapiro P; Kumar R; Passaniti A
    J Biol Chem; 2004 Oct; 279(41):42709-18. PubMed ID: 15304489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
    Ng SSW ; Tsao MS; Chow S; Hedley DW
    Cancer Res; 2000 Oct; 60(19):5451-5. PubMed ID: 11034087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of either phosphatidylinositol 3-kinase/Akt or the mitogen/extracellular-regulated kinase, MEK/ERK, signaling pathways suppress growth of breast cancer cell lines, but MEK/ERK signaling is critical for cell survival.
    Ripple MO; Kalmadi S; Eastman A
    Breast Cancer Res Treat; 2005 Sep; 93(2):177-88. PubMed ID: 16187238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
    Ng SS; Tsao MS; Nicklee T; Hedley DW
    Mol Cancer Ther; 2002 Aug; 1(10):777-83. PubMed ID: 12492110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
    Li J; Liang X; Yang X
    Oncol Rep; 2012 Aug; 28(2):501-10. PubMed ID: 22641480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways.
    Qiu Q; Yang M; Tsang BK; Gruslin A
    Reproduction; 2004 Sep; 128(3):355-63. PubMed ID: 15333786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
    Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
    Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition.
    Nelson JM; Fry DW
    J Biol Chem; 2001 May; 276(18):14842-7. PubMed ID: 11278435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.
    Yip-Schneider MT; Schmidt CM
    Pancreas; 2003 Nov; 27(4):337-44. PubMed ID: 14576498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
    Fryer RA; Barlett B; Galustian C; Dalgleish AG
    Anticancer Res; 2011 Nov; 31(11):3747-56. PubMed ID: 22110196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.